Comparative Pharmacology
Head-to-head clinical analysis: APTENSIO XR versus JORNAY PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APTENSIO XR versus JORNAY PM.
APTENSIO XR vs JORNAY PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Central alpha-2 adrenergic agonist that selectively stimulates alpha-2 adrenergic receptors in the brain stem, reducing sympathetic outflow and decreasing peripheral vascular resistance, heart rate, and blood pressure.
Methylphenidate is a central nervous system (CNS) stimulant. The mode of action in attention deficit hyperactivity disorder (ADHD) is not fully understood, but methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing the levels of these neurotransmitters in the extraneuronal space.
Oral, 20 mg once daily in the morning; may increase by 10–20 mg/day at 3-day intervals up to a maximum of 60 mg/day.
Initial: 20 mg orally once daily at bedtime; increase by 20 mg weekly as needed; max 100 mg/day.
None Documented
None Documented
The terminal elimination half-life of methylphenidate (IR and extended-release) is approximately 3-4 hours in children and 3.5-5 hours in adults. For Aptensio XR, the half-life is about 4-5 hours, supporting twice-daily dosing.
The terminal elimination half-life of methylphenidate following JORNAY PM administration is approximately 4-5 hours. This relatively short half-life necessitates the delayed-release/extended-release formulation to provide a prolonged duration of effect.
Methylphenidate is primarily excreted renally as metabolites (80-90%), with 1-3% excreted unchanged. Biliary/fecal elimination accounts for <5%.
Methylphenidate and its metabolites are primarily excreted in urine (approximately 90%) as metabolites (mainly ritalinic acid) with about 2% unchanged parent drug. Fecal excretion accounts for <1%.
Category C
Category C
CNS Stimulant
CNS Stimulant